The FDA has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with ...
Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...
Amgen and AstraZeneca’s Tezspire (tezepelumab-ekko) gains FDA approval as an add-on maintenance therapy for patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal ...
Waking up with a stuffy nose is common and usually caused by allergies, nasal inflammation, post-nasal drip, sleep position ...
Verywell Health on MSN
Can You Use Nasacort Every Day for Allergy Relief?
Nasacort takes up to a week to achieve full benefits for allergy symptoms, and should be used daily for optimal allergy ...
CENTER VALLEY, Pa., Oct. 8, 2025 /PRNewswire/ — Olympus Corporation of the Americas, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, will ...
Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published ...
The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...
The FDA approved Amgen's and AstraZeneca's drug to treat chronic rhinosinusitis with nasal polyps, an inflammatory condition of the sinuses and nasal passages. The companies said the approval was ...
New ‘concerning’ data find that most US endoscopists aren’t following current polypectomy guidelines for polyps < 1 cm, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback